D.E. Shaw & Co
LABP

D.E. Shaw & Co’s Landos Biopharma, Inc. Common Stock LABP Stock Holding History

D.E. Shaw & Co’s Portfolio LABP Stock Details LABP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,699
Closed -$25K – 5959
2022
Q1 		$25K Buy
+1,699
New +$43.2K ﹤0.01% 5303

Other funds holding LABP

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
AI
ArchPoint Investors Coral Gables, Florida $420M AUM 42.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co's LABP Position: Q2 2022 in Review

D.E. Shaw & Co sold out of Landos Biopharma, Inc. Common Stock (LABP) in Q2 2022, closing a stake of 1,699 shares — an estimated $25K sold.

D.E. Shaw & Co first reported a position in LABP in Q1 2022 and held it in 1 quarter. The position peaked at $25K in Q1 2022. 34 funds tracked by Wall St. Rank hold LABP as of Q2 2022.

  • D.E. Shaw & Co reported no remaining Landos Biopharma, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 1,699 Landos Biopharma, Inc. Common Stock shares in Q2 2022, an estimated $25K.
  • D.E. Shaw & Co first reported a position in Landos Biopharma, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • D.E. Shaw & Co's Landos Biopharma, Inc. Common Stock position peaked at $25K in Q1 2022.
  • 34 funds tracked by Wall St. Rank held Landos Biopharma, Inc. Common Stock as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.